Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People of any gender who have been diagnosed with breast cancer (as classified under standard medical coding systems ICD-9 or ICD-10).
- People who were aged 18 or older (or the legal age of consent in their country) at the time of their first breast cancer diagnosis.
- People whose breast cancer has been classified as Stage II or Stage III based on standard tumour staging guidelines set by the American Joint Committee on Cancer.
- People who have recently started adjuvant (post-surgery) treatment with either ribociclib or abemaciclib, combined with hormone-blocking therapy, within the 14 days before enrolling in the study.
- People whose cancer has tested positive for hormone receptors — either oestrogen receptors (ER+), progesterone receptors (PR+), or both — based on the most recent test taken on or before starting adjuvant treatment.
- People whose cancer has tested negative for the HER2 protein (HER2−), based on the most recent test taken on or before starting adjuvant treatment.
Who may not be able to join:
- People whose breast cancer had already come back locally or spread to other parts of the body before they started treatment with ribociclib or abemaciclib.
- People who were taking part in another clinical trial and receiving experimental treatment at any stage of care during the 12 months before enrolling in this study.
- People who are not able to understand the study requirements or complete the required data collection forms due to physical or mental reasons, and who would need a legal representative to act on their behalf (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Phone: +41613241111
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Invasive disease-free survival (iDFS); Distant disease-free survival (DDFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.